Research · head to head
Genedata vs Scispot

Genedata
Research
Enterprise R&D data platforms for biologics, screening and bioprocess, owned by Danaher
- From
- On request
- Rated
- -

Scispot
Research
No-code lab operating system combining LIMS, ELN and inventory for biotech teams
- From
- On request
- Rated
- -
The short version
- Each has a real cost: Genedata there is no entry level and no published price at any tier, so a mid-sized biotech cannot even establish whether Genedata is in its range without a lengthy sales engagement.; Scispot pricing is presented as four dollar sign bands with no figures, so a vendor whose marketing attacks competitor pricing opacity requires a discovery call before telling you its own numbers.
- They diverge on capability: Genedata covers Screener, Scispot covers No-code configuration.
- Prices and features above were last checked on 31 August 2026.
Where they differ
Only the attributes on which Genedata and Scispot actually diverge.
Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).
What each one covers
Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.
Only in Genedata
- Screener
- Biologics
- Bioprocess
- Expressionist
- Selector
- Profiler
- GxP-capable deployments
Only in Scispot
- No-code configuration
- LIMS and ELN together
- Inventory management
- Audit trails and e-signatures
- API and data layer
- Validation support
- Integrations
Both cover
- Instrument integration
What people use each for
The jobs each tool is most often brought in to do.
Genedata
- A pharmaceutical screening group processing thousands of plates a week where manual QC and curve fitting no longer scalenot Scispot
- A biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheetsnot Scispot
- A process development group standardising bioprocess run data across sites for modelling and scale-upnot Scispot
- A CRO delivering high-throughput screening results to sponsors that require documented, reproducible analysis pipelinesnot Scispot
Scispot
- A Series A biotech replacing a folder of spreadsheets before a partner or investor audit exposes the gapnot Genedata
- A diagnostics company that needs sample chain of custody and electronic signatures without a year-long LIMS implementationnot Genedata
- A contract research organisation configuring different workflows per client without buying a separate instance each timenot Genedata
- A computational team that wants laboratory data queryable through an API rather than exported by handnot Genedata
Where each one falls short
Documented limitations, not opinions. Every one is a constraint you would hit in normal use.
Genedata
- There is no entry level and no published price at any tier, so a mid-sized biotech cannot even establish whether Genedata is in its range without a lengthy sales engagement.
- Platforms are licensed individually and most organisations need two or three, so the real contract is a sum of separate licences plus the integration work between them.
- Deployment is a services programme rather than an installation, running months and requiring scientific configuration by the vendor, which means value arrives long after the first invoice.
- Danaher ownership since 2023 gives the roadmap a natural pull toward Danaher instrument and bioprocessing lines, which is an advantage on that hardware and a question to ask if your instrument estate is from competitors.
- Validated deployments for regulated use add scope, cost and an ongoing revalidation obligation on your side after each vendor release, and that recurring internal effort is rarely counted in the business case.
Scispot
- Pricing is presented as four dollar sign bands with no figures, so a vendor whose marketing attacks competitor pricing opacity requires a discovery call before telling you its own numbers.
- Compliance capability is bundled into tier scope rather than itemised, which makes it hard to tell at purchase whether the tier you are quoted actually covers the Part 11 controls your auditor will ask for.
- Validation remains your responsibility: the vendor supplies support and correctly states that no platform makes a lab compliant, but the documentation effort and its cost sit with your quality function.
- It is a young and small vendor holding your primary scientific record, so business continuity, data escrow and full export guarantees need to be settled contractually rather than assumed.
- Instrument integration breadth is narrower than the established LIMS vendors, so labs with older or unusual analysers may need custom connector work that undercuts the no-code promise.
Pricing, plan by plan
Genedata
On request- Genedata platform licence$undefined/year
- Each platform, such as Screener or Biologics, licensed separately
- Annual enterprise subscription scoped on users, sites and data volume
- Implementation and scientific configuration services quoted as a separate programme
Scispot
On request- Scispot$undefined/year
- Custom annual pricing released after a discovery call
- Four relative investment tiers shown only as dollar sign bands
- Mid tier adds roles, e-signatures, approvals, audit trails and validation support
Which should you pick?
Choose Genedata if
- You need screener.
- You work on Web, On-premise, Private cloud.
- You also want biologics.
Choose Scispot if
- You need no-code configuration.
- You work on Web, API.
- You also want lims and eln together.
Questions people ask
- Is Genedata or Scispot better?
- Neither clearly leads. Genedata starts at On request and Scispot at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
- Which is cheaper, Genedata or Scispot?
- Genedata starts at On request and Scispot at On request.
- Does Genedata or Scispot run on more platforms?
- Genedata runs on Web, On-premise, Private cloud. Scispot runs on Web, API.
- What is Genedata best used for?
- Genedata is most often used for a pharmaceutical screening group processing thousands of plates a week where manual qc and curve fitting no longer scale, a biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheets, a process development group standardising bioprocess run data across sites for modelling and scale-up, a cro delivering high-throughput screening results to sponsors that require documented, reproducible analysis pipelines. Of those, a pharmaceutical screening group processing thousands of plates a week where manual qc and curve fitting no longer scale and a biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheets are not what Scispot is typically brought in for.
- What can Genedata do that Scispot cannot?
- Genedata covers Screener, Biologics, Bioprocess, Expressionist. Scispot covers No-code configuration, LIMS and ELN together, Inventory management, Audit trails and e-signatures. Both handle Instrument integration.
Answered from the vendors’ own pages
Genedata: Who owns Genedata?
Danaher acquired the company in 2023. It remains headquartered in Basel and continues under the Genedata name.
Scispot: How much does Scispot cost?
It does not publish figures. The pricing page shows four relative investment tiers as dollar sign bands, with real numbers given after a discovery call.
Genedata: Is there a small-team or starter option?
No. Everything is an enterprise contract scoped by users, sites and data volume, with services attached.
Scispot: Does it support 21 CFR Part 11?
It can be configured for Part 11 controlled workflows with roles, e-signatures, approvals and audit trails from the mid tier, and it supports ALCOA+ principles. Validation of your configuration is still your responsibility.
Genedata: Do I buy one product or the whole suite?
Each platform is licensed separately. Most customers license two or three and integrate between them.
Scispot: Is it a LIMS or an ELN?
Both, plus inventory, in one subscription rather than separately licensed products.
Genedata: Can it be used in a GxP environment?
Yes, with a validated deployment contracted as additional scope. Ongoing revalidation after releases remains your responsibility.
Scispot: Who is it not for?
Large regulated manufacturers with existing validated LIMS estates, and any lab that needs deep integration with an unusual analyser fleet.
Related pages
Other head to heads
- Genedata vs LabVantage
- Genedata vs Benchling
- Genedata vs Sapio Sciences
- Genedata vs Medidata Rave
- Genedata vs Castor EDC
- Genedata vs Suzy
- Genedata vs Terra
- Genedata vs LabWare
- Genedata vs Aurelius
- Genedata vs Chemaxon
- Genedata vs Labguru
- Genedata vs Schrodinger
- Genedata vs TetraScience
- Genedata vs Thermo SampleManager LIMS
- Genedata vs Valispace
- Genedata vs Wolfram Mathematica
- Genedata vs STARLIMS
- Genedata vs LabArchives
- Genedata vs Dotmatics
- Genedata vs GWI
- Genedata vs Marvin
- Genedata vs OpenEye, Cadence Molecular Sciences
- Genedata vs Paperpile
- Genedata vs Reduct
- Genedata vs Remesh
- Scispot vs LabVantage
- Scispot vs Benchling
- Scispot vs Sapio Sciences
- Scispot vs Medidata Rave
- Scispot vs Castor EDC
- Scispot vs Suzy
- Scispot vs Terra
- Scispot vs LabWare
- Scispot vs Aurelius
- Scispot vs Chemaxon
- Scispot vs Labguru
- Scispot vs Schrodinger
- Scispot vs TetraScience
- Scispot vs Thermo SampleManager LIMS
- Scispot vs Valispace
- Scispot vs Wolfram Mathematica
- Scispot vs STARLIMS
- Scispot vs LabArchives
- Scispot vs Dotmatics
- Scispot vs GWI
- Scispot vs Marvin
- Scispot vs OpenEye, Cadence Molecular Sciences
- Scispot vs Paperpile
- Scispot vs Reduct
- Scispot vs Remesh
